2,157 Johnson & Johnson $JNJ Shares Acquired by Parallel Advisors LLC

Posted by Stanley Muller on Nov 8th, 2026

Parallel Advisors LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 2.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 85,192 shares of the company’s stock after purchasing an additional 2,157 shares during the quarter. Parallel Advisors LLC’s holdings in Johnson & Johnson were worth $22,554,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Prudent Man Investment Management Inc. boosted its holdings in shares of Johnson & Johnson by 68.3% during the third quarter. Prudent Man Investment Management Inc. now owns 589 shares of the company’s stock valued at $156,000 after acquiring an additional 239 shares during the period. Plancorp LLC grew its position in shares of Johnson & Johnson by 9.9% during the third quarter. Plancorp LLC now owns 15,715 shares of the company’s stock worth $4,293,000 after acquiring an additional 1,415 shares during the last quarter. May Hill Capital LLC increased its holdings in shares of Johnson & Johnson by 6.0% in the 3rd quarter. May Hill Capital LLC now owns 5,713 shares of the company’s stock worth $1,512,000 after acquiring an additional 321 shares during the period. LightSquare Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 6.2% in the 3rd quarter. LightSquare Wealth Management LLC now owns 2,012 shares of the company’s stock worth $533,000 after acquiring an additional 117 shares during the period. Finally, Ashton Thomas Private Wealth LLC lifted its position in Johnson & Johnson by 1.1% in the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 57,248 shares of the company’s stock valued at $15,156,000 after purchasing an additional 638 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Freedom Capital upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 16th. Raymond James Financial set a $280.00 price target on Johnson & Johnson in a report on Monday, August 3rd. Bank of America reiterated a “neutral” rating and set a $278.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, September 29th. Finally, Evercore set a $300.00 price objective on Johnson & Johnson in a report on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $275.92.

Read Our Latest Stock Report on JNJ

Johnson & Johnson Trading Up 1.4%

Shares of Johnson & Johnson stock opened at $276.14 on Friday. The business has a fifty day simple moving average of $265.91 and a 200-day simple moving average of $248.30. Johnson & Johnson has a fifty-two week low of $185.12 and a fifty-two week high of $282.02. The firm has a market cap of $664.76 billion, a price-to-earnings ratio of 41.84, a price-to-earnings-growth ratio of 2.73 and a beta of 0.22. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same period in the previous year, the company earned $2.80 earnings per share. Johnson & Johnson’s revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities analysts forecast that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s payout ratio is presently 81.21%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: The FDA granted accelerated approval to RYBREVANT FASPRO as a single-agent treatment for certain adults with recurrent or metastatic head and neck cancer after prior platinum chemotherapy and immunotherapy. J&J says the treatment is the first new option in this setting in a decade; trial data showed a 42% response rate. The approval extends the drug’s use beyond lung cancer and could broaden its commercial opportunity, though the indication is limited and accelerated approval may require confirmatory evidence. FDA approval announcement
Positive Sentiment: J&J’s Innovative Medicine division grew third-quarter sales 7.7% to $16.76 billion, with established blockbusters and new launches more than offsetting generic competition. Continued growth despite patent-related headwinds supports the business outlook. Innovative Medicine sales report
Neutral Sentiment: J&J was included in an article highlighting companies with a history of dividend increases and strong balance sheets. This reinforces its income-investor appeal, but the article does not identify a new company-specific dividend announcement. Dividend raisers article
Negative Sentiment: Pomerantz LLP announced it is investigating potential claims on behalf of J&J investors. The notice does not provide details of the claims, but the investigation could add legal and reputational uncertainty. Investor investigation announcement

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.